Pfizer Inc PFE

$28.67 +0.26 (0.92%)

Valuation

Market cap
161,927,728,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.24
Forward PE
9.46
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
27,763,600
Avg volume
36,399,605
Day's range
$28.17 – $28.69
Shares out
5,699,674,000
Stochastic %K
89%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

KreeBull Sep 26, 10:17 AM
$PFE if you guys want the best risk reward stock with little risk check out $NLST hold for 12-24 months and see
0 replies
BigAllergies Sep 26, 12:14 AM
$PFE Came up on the scanner at a 17
0 replies
Kevin__P Sep 25, 9:39 PM
$PFE I added at the morning dip and closed green. Nice solid close! 
0 replies
WuTangClam Sep 25, 8:53 PM
$PFE was a great pick up for me at 23$ .. with the AI advancement this is not going anywhere but up. That's 6% yield is wild
0 replies
sam92 Sep 25, 8:32 PM
$PFE Pfizer shares rose for seven consecutive sessions
1 replies
Tman1123 Sep 25, 8:30 PM
$PFE I’m as hard as Viagra watching this price action
0 replies
Mountainmannn Sep 25, 7:46 PM
$ABUS if you believe in $BITI Bitcoin or $ Solana supply and demand. This auction should be results 30%-+ value added to 1.5 billion in cash from $MRNA , everyone knows they are just going to pay it or buy us now we won it's a non-issue. Another at least 1.5b minimum from $PFE . Hep B functional cure fast track. Original market cap 900 million+ 30%, let's say 30% for the rest is 90% with no P/E multiple or new NLP customers. Ee may already have a deal with $MRNA on their new Cancer drug with delivery. We will get more information on that next month and in November. I only see catalyst, but shorts will trick you into thinking you missed out first, buy the dip if it comes... Long hold! Cash Kings!!
1 replies
SellasgpsCurativeBAT11 Sep 25, 7:21 PM
$RVMD $SLS $JNJ $PFE Big pharmaceutical Suitor BO Monday. Everything in place not to make a move because they don’t want to repeat $RVMD $44 Billion MC post data. ✌️🙏❤️‍🩹
0 replies